Rare disease player that went public in biotech's go-go years merges with specialty pharma in all-stock deal — at a fraction of the debut price

Strongbridge Biopharma went public in the summer of 2015, the tail end of a biotech boom on Nasdaq, with a solid pitch. Almost 20 …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Rare dis­ease play­er that went pub­lic in biotech's go-go years merges with spe­cial­ty phar­ma in all-stock deal — at a frac­tion of the de­but price